The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project

Overview

Journal Invest Ophthalmol Vis Sci

Specialty Ophthalmology

Date 2008 Jul 1

PMID 18586874

Citations 33

Authors

Traci E Clemons

Mark C Gillies

Emily Y Chew

Alan C Bird

Tunde Peto

Maria Figueroa

Molly W Harrington

Affiliations

Soon will be listed here.

Abstract

Purpose: To describe vision-targeted health-related quality of life (HR-QOL), measured with the National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25) in a cohort of patients with macular telangiectasia (MacTel) type 2 and to evaluate the relationship between visual acuity and NEI-VFQ-25 scores.

Methods: This was an analysis of cross-sectional baseline data from a longitudinal natural history study. Patients with MacTel type 2 were enrolled in the Natural History Study of The Macular Telangiectasia Project (The MacTel Project). NEI-VFQ-25 were completed at enrollment. Linear correlation and regression analyses were used to relate baseline NEI-VFQ-25 overall and subscale scores to visual acuity.

Results: Participants reported lower vision-related functioning measured by the NEI-VFQ-25 in most of the domains measured by the NEI VFQ compared with that of a normal reference group (P < 0.001 for all domains except color vision). Visual acuity was found to be associated with the NEI-VFQ-25 in many of the domains measuring degree of difficulty with common visual activities.

Conclusions: This is the first cross-sectional cohort study to assess vision targeted HR-QOL in patients with MacTel type 2. Patients with MacTel type 2 reported markedly reduced visual functioning compared to reports of a normal reference group. These findings provide support to the use of the NEI-VFQ-25 in patients with MacTel type 2 to measure the effect of disease and potential therapies on vision-targeted HR-QOL.

Citing Articles

Genetic Background of Macular Telangiectasia Type 2.

Kuncic A, Urbancic M, Dobovsek Divjak D, Hudler P, Debeljak N Int J Mol Sci. 2025; 26(2).

PMID: 39859398 PMC: 11765629. DOI: 10.3390/ijms26020684.

Dogra N, Redmond B, Lilley S, Johnson B, Lam B, Tamhankar M Brain Behav. 2024; 14(7):e3582.

PMID: 38956813 PMC: 11219293. DOI: 10.1002/brb3.3582.

Unraveling the mysteries of macular telangiectasia 2: the intersection of philanthropy, multimodal imaging and molecular genetics. The 2022 founders lecture of the pan American vitreoretinal society.

Wu L Int J Retina Vitreous. 2023; 9(1):69.

PMID: 37968753 PMC: 10652610. DOI: 10.1186/s40942-023-00505-5.

Macular Telangiectasia Type 2: A Classification System Using MultiModal Imaging MacTel Project Report Number 10.

Chew E, Peto T, Clemons T, Sallo F, Pauleikhoff D, Leung I Ophthalmol Sci. 2023; 3(2):100261.

PMID: 36846105 PMC: 9944556. DOI: 10.1016/j.xops.2022.100261.

Genetic disruption of serine biosynthesis is a key driver of macular telangiectasia type 2 aetiology and progression.

Bonelli R, Ansell B, Lotta L, Scerri T, Clemons T, Leung I Genome Med. 2021; 13(1):39.

PMID: 33750426 PMC: 7945323. DOI: 10.1186/s13073-021-00848-4.

References

GASS J, Oyakawa R . Idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol. 1982; 100(5):769-80. DOI: 10.1001/archopht.1982.01030030773010. View

Yannuzzi L, Bardal A, Freund K, Chen K, Eandi C, Blodi B . Idiopathic macular telangiectasia. Arch Ophthalmol. 2006; 124(4):450-60. DOI: 10.1001/archopht.124.4.450. View

Klein R, Moss S, Klein B, Gutierrez P, Mangione C . The NEI-VFQ-25 in people with long-term type 1 diabetes mellitus: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol. 2001; 119(5):733-40. DOI: 10.1001/archopht.119.5.733. View

Cole S, Beck R, Moke P, Gal R, Long D . The National Eye Institute Visual Function Questionnaire: experience of the ONTT. Optic Neuritis Treatment Trial. Invest Ophthalmol Vis Sci. 2001; 41(5):1017-21. View

Chia E, Mitchell P, Ojaimi E, Rochtchina E, Wang J . Assessment of vision-related quality of life in an older population subsample: The Blue Mountains Eye Study. Ophthalmic Epidemiol. 2006; 13(6):371-7. DOI: 10.1080/09286580600864794. View

Schiffman R, Jacobsen G, Whitcup S . Visual functioning and general health status in patients with uveitis. Arch Ophthalmol. 2001; 119(6):841-9. DOI: 10.1001/archopht.119.6.841. View

Maguire M . Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). Ophthalmology. 2004; 111(7):1307-16. DOI: 10.1016/j.ophtha.2003.10.031. View

Bailey I, Lovie J . New design principles for visual acuity letter charts. Am J Optom Physiol Opt. 1976; 53(11):740-5. DOI: 10.1097/00006324-197611000-00006. View

GASS J, Blodi B . Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology. 1993; 100(10):1536-46. View

10.

Nichols K, Mitchell G, Zadnik K . Performance and repeatability of the NEI-VFQ-25 in patients with dry eye. Cornea. 2002; 21(6):578-83. DOI: 10.1097/00003226-200208000-00009. View

11.

Charbel Issa P, Helb H, Rohrschneider K, Holz F, Scholl H . Microperimetric assessment of patients with type 2 idiopathic macular telangiectasia. Invest Ophthalmol Vis Sci. 2007; 48(8):3788-95. DOI: 10.1167/iovs.06-1272. View

12.

Ferris 3rd F, Kassoff A, Bresnick G, Bailey I . New visual acuity charts for clinical research. Am J Ophthalmol. 1982; 94(1):91-6. View

13.

Mangione C, Berry S, Spritzer K, Janz N, Klein R, Owsley C . Identifying the content area for the 51-item National Eye Institute Visual Function Questionnaire: results from focus groups with visually impaired persons. Arch Ophthalmol. 1998; 116(2):227-33. DOI: 10.1001/archopht.116.2.227. View

14.

GASS J . A fluorescein angiographic study of macular dysfunction secondary to retinal vascular disease. V. Retinal telangiectasis. Arch Ophthalmol. 1968; 80(5):592-605. DOI: 10.1001/archopht.1968.00980050594005. View

15.

Mangione C, Lee P, Gutierrez P, Spritzer K, Berry S, Hays R . Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001; 119(7):1050-8. DOI: 10.1001/archopht.119.7.1050. View

16.

Brody B, Gamst A, Williams R, Smith A, Lau P, Dolnak D . Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology. 2001; 108(10):1893-900; discussion 1900-1. DOI: 10.1016/s0161-6420(01)00754-0. View

17.

. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology. 1991; 98(5 Suppl):741-56. DOI: 10.1016/s0161-6420(13)38009-9. View

18.

Parrish 2nd R, Gedde S, Scott I, Feuer W, Schiffman J, Mangione C . Visual function and quality of life among patients with glaucoma. Arch Ophthalmol. 1997; 115(11):1447-55. DOI: 10.1001/archopht.1997.01100160617016. View

19.

Mangione C, Lee P, Pitts J, Gutierrez P, Berry S, Hays R . Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol. 1998; 116(11):1496-504. DOI: 10.1001/archopht.116.11.1496. View

20.

. Health- and vision-related quality of life among patients with ocular histoplasmosis or idiopathic choroidal neovascularization at enrollment in a randomized trial of submacular surgery: Submacular Surgery Trials Report No. 5. Arch Ophthalmol. 2005; 123(1):78-88. PMC: 1256027. DOI: 10.1001/archopht.123.1.78. View